Brokerages Expect Spero Therapeutics Inc (SPRO) to Post -$0.88 EPS

Analysts expect Spero Therapeutics Inc (NASDAQ:SPRO) to post earnings per share (EPS) of ($0.88) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Spero Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.09) and the highest estimate coming in at ($0.67). The firm is scheduled to report its next earnings report on Thursday, August 9th.

On average, analysts expect that Spero Therapeutics will report full year earnings of ($3.33) per share for the current year, with EPS estimates ranging from ($3.95) to ($2.81). For the next financial year, analysts expect that the firm will post earnings of ($4.48) per share, with EPS estimates ranging from ($7.52) to ($3.30). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that cover Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Thursday, May 10th. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.46. The firm had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.20 million.

Several research firms recently commented on SPRO. Oppenheimer set a $30.00 price objective on shares of Spero Therapeutics and gave the stock a “buy” rating in a research note on Sunday, May 13th. Cantor Fitzgerald set a $27.00 price target on shares of Spero Therapeutics and gave the company a “buy” rating in a research note on Monday, April 30th. HC Wainwright initiated coverage on shares of Spero Therapeutics in a research note on Friday, May 11th. They set a “buy” rating and a $28.00 price target on the stock. ValuEngine upgraded shares of Spero Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research upgraded shares of Spero Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 21st. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $25.00.

A number of institutional investors have recently modified their holdings of the business. BVF Inc. IL increased its stake in Spero Therapeutics by 1.9% during the 1st quarter. BVF Inc. IL now owns 1,048,958 shares of the company’s stock valued at $14,948,000 after purchasing an additional 19,773 shares in the last quarter. Rock Springs Capital Management LP acquired a new position in Spero Therapeutics during the 4th quarter valued at approximately $6,169,000. VHCP Management II LLC acquired a new position in Spero Therapeutics during the 4th quarter valued at approximately $5,706,000. AWM Investment Company Inc. acquired a new position in Spero Therapeutics during the 4th quarter valued at approximately $4,112,000. Finally, JPMorgan Chase & Co. increased its stake in Spero Therapeutics by 19,604.3% during the 1st quarter. JPMorgan Chase & Co. now owns 256,353 shares of the company’s stock valued at $3,653,000 after purchasing an additional 255,052 shares in the last quarter. Institutional investors and hedge funds own 45.90% of the company’s stock.

NASDAQ SPRO opened at $14.50 on Thursday. The company has a market cap of $163.66 million and a P/E ratio of -0.81. Spero Therapeutics has a 52 week low of $9.66 and a 52 week high of $19.00.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply